Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFκB activity in Follicular Lymphoma

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1699-1702

  Green, Michael R ^a   Gandhi, Maher K ^a,b,c   Courtney, Mark J ^d   Marlton, Paula ^c   Griffiths, Lyn ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

Follicular Lymphoma; FOXP1; NF B; Non Hodgkin's Lymphoma

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN TISSUE; MARKER GENE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOMA, FOLLICULAR; NF-KAPPA B; PROTEIN ISOFORMS; REPRESSOR PROTEINS; RNA, MESSENGER;

EID: 70249122331     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.05.004     Document Type: Article

References (12)

1. Gandhi M., and Marcus R. Follicular lymphoma: time for a re-think?. Blood Rev 19 (2005) 165-178
2. Brown P., Marafioti T., Kusec R., and Banham A. The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma. J Mol Histol 36 (2005) 249-256
3. Barrans S., Fenton J., Banham A., Owen R., and Jack A. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104 (2004) 2933-2935
4. Banham A., Beasley N., Campo E., Dernandez P., Fidler C., Gatter K., et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61 (2001) 8820-8829
5. Alimov A., Kost-Alimov M., Liu J., Li C., Bergerheim U., Imrech S., et al. Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma. Oncogene 19 (2000) 1392-1399
6. Banham A., Connors J., Brown P., Cordell J., Ott G., Sreenivasan G., et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11 (2005) 1065-1072
7. Wlodarska I., Veyt E., De Paepe P., Vandenberghe P., Nooijen P., Theate I., et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 19 (2005) 1299-1305
8. Wang B., Lin D., Li C., and Tucker P. Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem 278 (2003) 24259-24268
9. Brown P., Ashe S., Leich E., Burek C., Barrans S., Fenton J., et al. Potentially oncogenic B-cell activation induced smaller isoforms of FOXP1 are highly expressed in the activated B-cell-like subtype of DLBCL. Blood 111 (2008) 2816-2824
10. Pajer P., Peënka V., Králová J., Karafiát V., Prüková D., Zemanová Z., et al. Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 66 (2006) 78-86
11. Li S., Weidenfeld J., and Morrisey E. Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol Cell Biol 24 (2004) 809-822
12. Shipp M., Ross K., Tamayo P., Weng A., Kutok J., Aguiar R., et al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat Genet 8 (2002) 69-74